CompletedPhase 3

Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients

Egypt75 participantsStarted 2020-09-25

Plain-language summary

study the effect of radiotherapy to the primary lesion after first line systemic therapy in metastatic non-small cell lung cancer patients.

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Confirmed histological diagnosis of NSCLC.
. Stage IV disease.
. Patients with P.S ≤ 2.
. finished at least 4 cycles of platinum-based doublet chemotherapy if patient has no diver mutation, or at least 3 months of anti-EGFR, Anti-ALK according to their driver mutation with SD, PR or CR.

Exclusion criteria

. History of prior irradiation to the lung.
. residual Malignant pleural or pericardial effusion at randomization time.
. History of prior malignant tumor likely to interfere with the treatment protocol.
. Severe comorbidities as measured by morbidity index.
. Disease progression on first line systemic therapy.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

progression free survival

Timeframe: six months

patients quality of life

Timeframe: six months

Trial details

NCT IDNCT04776083

SponsorMenoufia University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-11-25

View on ClinicalTrials.gov More Non-Small Cell Carcinoma of Lung, TNM Stage 4 trials

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Confirmed histological diagnosis of NSCLC.
. Stage IV disease.
. Patients with P.S ≤ 2.
. finished at least 4 cycles of platinum-based doublet chemotherapy if patient has no diver mutation, or at least 3 months of anti-EGFR, Anti-ALK according to their driver mutation with SD, PR or CR.

Exclusion criteria

. History of prior irradiation to the lung.
. residual Malignant pleural or pericardial effusion at randomization time.
. History of prior malignant tumor likely to interfere with the treatment protocol.
. Severe comorbidities as measured by morbidity index.
. Disease progression on first line systemic therapy.